|
2024 Conference Publication Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell LymphomaLewis, Katharine L., Giri, Pratyush, Marconi, Tamara, Blombery, Piers, Keane, Colm, Sungala, Nagendra Prasad, Cochrane, Tara, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Francis, Roslyn, Walia, Mannu, Carlson, Julia, Butcher, Belinda E. and Cheah, Chan Y. (2024). Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204317 |
|
2024 Conference Publication Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation PlanningKoh, Eng-Siew, Francis, Roslyn, Lee, SzeTing, Lau, Eddie, Thomas, Elizabeth, Whitehead, Angela, Cook, Olivia, Dykyj, Rachael, Moore, Alisha, Rossi, Alana, Thomas, Paul, Pattison, David, Akhurst, Tim, Alipour, Ramin, Hsiao, Edward, Schembri, Geoffrey, Lin, Peter, Yap, June, Ly, Tam, Kirkwood, Ian, Vallat, Wilson, Krishna, Dayanethee Krishna, Khan, Shahroz Khan, Ngai, Stanley Ngai, Yu, Chris, Beuzeville, Scott, Yeow, Tow Chan, Barry, Nathaniel, Ebert, Martin ... Scott, Andrew M. (2024). Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation Planning. 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, Houston, TX United States, 21-24 November 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/neuonc/noae165.0806 |
|
2024 Conference Publication A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)Azad, A.A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A.J., Guminski, A., Francis, R.J., Saghebi, J., Dhiantravan, N., Joshua, A., Emmett, L., Murphy, D., Hsiao, E., Lee, S.T., Pattison, D.A., Nadebaum, D., Kirkwood, I.D. and Hofman, M.S. (2024). A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.2309 |
|
2024 Conference Publication The feasibility of peri-coronary fat attenuation analysis on non-contrast cardiac CT and association with microcalcification activityBellinge, Brynn, Smith, B., Bellinge, J., Francis, R. and Schultz, C. (2024). The feasibility of peri-coronary fat attenuation analysis on non-contrast cardiac CT and association with microcalcification activity. RACP Congress 2024, Shaping Healthcare, Sydney, NSW, Australia, 16-17 May 2024. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/imj.16_16398 |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication A prospective, multi-centre trial of FET-PET In Glioblastoma patients - the TROG 18.06 FIG Study: results of the Nuclear Medicine and Radiation Oncology credentialing programKoh, E. S., Moore, A., Francis, R. J., Ebert, M. A., Gan, H. K., Lee, S. T., Lau, E., Rossi, A., Grose, A., Ng, S. P., Barnes, E. H., Moffat, B. A., Scott, F. E., Adda, L., Foroudi, F., Nowak, A. K., Bailey, D. L., Back, M., Lourenco, R. De Abreu and Scott, A. M. (2022). A prospective, multi-centre trial of FET-PET In Glioblastoma patients - the TROG 18.06 FIG Study: results of the Nuclear Medicine and Radiation Oncology credentialing program. HOBOKEN: WILEY. |
|
2022 Conference Publication ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S., Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R. and Davis, Ian D. (2022). ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS205 |
|
2022 Conference Publication PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Buteau, James Patrick, Martin, Andrew James, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen Kaur, Joshua, Anthony M., Zhang, Alison Yan, Francis, Roslyn J., Scott, Andrew Mark, Azad, Arun, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Davis, Ian D. and Hofman, Michael S. (2022). PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.010 |
|
2019 Conference Publication Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning MeetingGill, Ritu R., Tsao, Anne S., Kindler, Hedy L., Richards, William G, Armato, Samuel G., Francis, Roslyn J., Gomez, Daniel R., Dahlberg, Suzanne, Rimner, Andreas, Simone, Charles B., de Perrot, Marc, Blumenthal, Gideon, Adjei, Alex A., Bueno, Raphael, Harpole, David H., Hesdorffer, Mary, Hirsch, Fred R., Pass, Harvey I., Yorke, Ellen, Rosenzweig, Kenneth, Burt, Bryan, Fennell, Dean A., Lindwasser, Wolf, Malik, Shakun, Peikert, Tobias, Mansfield, Aaron S., Salgia, Ravi, Yang, Haining, Rusch, Valerie W. and Nowak, Anna K. (2019). Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Elsevier Inc. doi: 10.1016/j.jtho.2019.08.012 |
|
2019 Conference Publication Test-Retest Repeatability of 18F-FET PET in Small VolumesFerjancic, P., Ebert, M. A., Nowak, A. K., Francis, R. J. and Jeraj, R. (2019). Test-Retest Repeatability of 18F-FET PET in Small Volumes. Annual Meeting of the American-Association-of-Physicists-in-Medicine (AAPM), San Antonio Tx, Jul 14-18, 2019. HOBOKEN: WILEY. |
|
2017 Conference Publication Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre studyRoach, Paul, Francis, Roslyn, Emmett, Louise, McCarthy, Michael and Scott, Andrew (2017). Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre study. Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Denver, CO United States, 10-14 June 2017. Reston, VA United States: Society of Nuclear Medicine. |
|
2017 Conference Publication ATYPICAL FOR PROSTATE METASTASISCulleton, S. and Francis, R. (2017). ATYPICAL FOR PROSTATE METASTASIS. HOBOKEN: WILEY. |
|
2017 Conference Publication A RARE CASE OF MERKEL CELL CARCINOMA CARDIAC METASTASIS CAUSING CARDIAC TAMPONADE: REVIEW OF THE ROLE OF FDG PET IN MERKEL CELL CARCINOMADi Loreto, M., Millward, M. and Francis, R. (2017). A RARE CASE OF MERKEL CELL CARCINOMA CARDIAC METASTASIS CAUSING CARDIAC TAMPONADE: REVIEW OF THE ROLE OF FDG PET IN MERKEL CELL CARCINOMA. HOBOKEN: WILEY. |
|
2014 Conference Publication Characterization of the effect of pleurodesis on FLT and FDG PET/CT imaging in malignant pleural mesothelioma (MPM)Francis, Roslyn, Nowak, Anna, Segard, Tatiana, Morandeau, Laurence, Lee, Gary, Boucek, Jan and Millward, Michael (2014). Characterization of the effect of pleurodesis on FLT and FDG PET/CT imaging in malignant pleural mesothelioma (MPM). Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), St Louis Mo, Jun 07-11, 2014. RESTON: SOC NUCLEAR MEDICINE INC. |
|
2011 Conference Publication CHARACTERISATION AND PROGNOSTIC SIGNIFICANCE OF GLOBAL AND REGIONAL HYPOXIA IN MESOTHELIOMA USING 18F-MISO PET/CT IMAGINGSegard, Tatiana M. L., Nowak, Anna K., Lee, Y. C. Gary, Millward, Michael, Morandeau, Laurence M. J. A., Campbell, Elaine M. and Francis, Roslyn J. (2011). CHARACTERISATION AND PROGNOSTIC SIGNIFICANCE OF GLOBAL AND REGIONAL HYPOXIA IN MESOTHELIOMA USING 18F-MISO PET/CT IMAGING. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2011 Conference Publication FINAL RESULTS OF A PHASE II STUDY OF SUNITINIB AS SECOND LINE THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA (MPM)Nowak, A. K., Francis, R. J., Millward, M. J., van der Schaaf, A., Seguard, T., Creaney, J., Hasani, A., Musk, A. W. and Byrne, M. J. (2011). FINAL RESULTS OF A PHASE II STUDY OF SUNITINIB AS SECOND LINE THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA (MPM). 3rd Australian Lung Cancer Conference (ALCC), Melbourne Australia, Oct 07-09, 2010. NEW YORK: ELSEVIER SCIENCE INC. |
